Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61.

Article  PubMed  PubMed Central  Google Scholar 

Lyons TG. Targeted therapies for triple-negative breast cancer. Curr Treat Options in Oncol. 2019;20(11):82.

Article  Google Scholar 

Asleh K, Riaz N, Nielsen TO. Heterogeneity of triple negative breast cancer: current advances in subtyping and treatment implications. J Exp Clin Cancer Res. 2022;41(1):265.

Article  PubMed  PubMed Central  Google Scholar 

Kordias D, Kostara CE, Papadaki S, Verigos J, Bairaktari E, Magklara A. Omics analysis of chemoresistant triple negative breast cancer cells reveals novel metabolic vulnerabilities. Cells. 2022;11(17):2719.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Lehmann BD, Colaprico A, Silva TC, Chen J, An H, Ban Y, et al. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun. 2021;12(1):6276. TNBC is a heterogenous group of cancers characterized by distinct transcriptional patterns, biology and immune composition. Subtypes include basal-like 1, basal-like 2, mesenchymal, and luminal androgen receptor with differences in transcriptomic, proteomic, and epigenetic expression

Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. npj Breast Cancer. 2020;6(1):54.

Article  PubMed  PubMed Central  Google Scholar 

Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell. 2018;173(4):879-893.e13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koren S, Bentires-Alj M. Breast tumor heterogeneity: source of fitness, hurdle for therapy. Mol Cell. 2015;60(4):537–46.

Article  CAS  PubMed  Google Scholar 

van der Noord VE, van de Water B, Le Dévédec SE. Targeting the heterogeneous genomic landscape in triple-negative breast cancer through inhibitors of the transcriptional machinery. Cancers. 2022;14(18):4353

• Zagami P, Carey LA. Triple negative breast cancer: pitfalls and progress. npj Breast Cancer. 2022;8(1):95. This review is important because it gives a thorough overview of preclinical and clinical investigations into therapies for TNBC that have been effective, and discusses therapies that have proven to not have be effective in TNBC. This review provides a discussion regarding why it is important to learn crucial lessons from failed therapies and this can benefit future endeavors to discovery novel treatments.

Nandini D, Jennifer A, Pradip D. Therapeutic strategies for metastatic triple-negative breast cancers: from negative to positive. Pharmaceuticals. 2021;14(5):455.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019;20(3):e175–86.

Article  CAS  PubMed  Google Scholar 

Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw. 2020;18(4):479–89.

Article  CAS  PubMed  Google Scholar 

Savas P, Loi S. Expanding the role for immunotherapy in triple-negative breast cancer. Cancer Cell. 2020;37(5):623–4.

Article  CAS  PubMed  Google Scholar 

Wojtukiewicz MZ, Pogorzelska M, Politynska B. Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end? Cancer Metastasis Rev. 2022;41(3):465–9.

Article  PubMed  PubMed Central  Google Scholar 

Nanda R, Chow LQM, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 Study. JCO. 2016;34(21):2460–7.

Article  CAS  Google Scholar 

Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):397–404.

Article  CAS  PubMed  Google Scholar 

Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5(1):74.

Article  PubMed  Google Scholar 

Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(4):499–511.

Article  CAS  PubMed  Google Scholar 

Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. The Lancet. 2020;396(10265):1817–28.

Article  Google Scholar 

Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021;32(8):983–93.

Article  CAS  PubMed  Google Scholar 

Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994–1004.

Article  CAS  PubMed  Google Scholar 

Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676.

Article  PubMed  Google Scholar 

Schmid P, Cortés J, Dent R, Pusztai L, McArthur HL, Kuemmel S, et al. KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC). Ann Oncol. 2019;30:v853–4.

Article  Google Scholar 

•• Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–21. In patients with high risk early stage TNBC, the addition of pembrolizumab to chemotherapy significantly increased the percentage of patients with a pathological complete response

Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279–88.

Article  CAS  PubMed  Google Scholar 

He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660–9.

Article  PubMed  PubMed Central  Google Scholar 

Barroso-Sousa R, Li T, Reddy S, Emens LA, Overmoyer B, Lange P, et al. Abstract GS2–10: Nimbus: a phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC). Cancer Res. 2022;82(4_Supplement):GS2–10-GS2–10.

Adams S, Othus M, Patel SP, Miller KD, Chugh R, Schuetze SM, et al. A multicenter phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART, SWOG S1609). Clin Cancer Res. 2022;28(2):271–8.

Article  CAS  PubMed  Google Scholar 

Stovgaard ES, Kümler I, List-jensen K, Roslind A, Christensen IJ, Høgdall E, et al. Prognostic and clinicopathologic associations of LAG-3 expression in triple-negative breast cancer. Appl Immunohistochem Mol Morphol. 2022;30(1):62–71.

Article  CAS  PubMed  Google Scholar 

Isaacs C, Nanda R, Chien J, Trivedi MS, Stringer-Reasor E, Vaklavas C, et al. Evaluation of anti-PD-1 cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: results from the neoadjuvant I-SPY 2 trial. Abstract GS5–03. 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6; San Antonio, TX.

Maute R, Xu J, Weissman IL. CD47–SIRPα-targeted therapeutics: status and prospects. Immuno-Oncol Technol. 2022;13:100070.

Article  CAS  Google Scholar 

Han Y, Yu X, Li S, Tian Y, Liu C. New perspectives for resistance to PARP inhibitors in triple-negative breast cancer. Front Oncol. 2020;25(10):578095.

Article  Google Scholar 

Zhu X, Chen L, Huang B, Li X, Yang L, Hu X, et al. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer. J Exp Clin Cancer Res. 2021;40(1):122.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uliano J, Nicolò E, Corvaja C, Taurelli Salimbeni B, Trapani D, Curigliano G. Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape. Expert Rev Clin Pharmacol. 2022;15(12):1399–413.

Article  CAS  PubMed  Google Scholar 

Clark CA, Yang ES. Harnessing DNA repair defects to augment immune-based therapies in triple-negative breast cancer. Front Oncol. 2021;24(11):703802.

Article  Google Scholar 

Vinayak S, Tolaney SM, Schwartzberg LS, Mita MM, McCann GAL, Tan AR, et al. TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. JCO. 2018;36(15_suppl):1011–1011.

Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21(9):1155–64.

Article  CAS  PubMed  Google Scholar 

• Luo C, Wang P, He S, Zhu J, Shi Y, Wang J. Progress and prospect of immunotherapy for triple-negative breast cancer. Front Oncol. 2022;12:919072. This review discusses the progress and future directions of immunotherapy in TNBC including immune checkpoint inhibitors, oncolytic virus-based therapies, and cellular therapies

Isakoff SJ, Adams S, Soliman HH, Tung N, Barry WT, Hu J, et al. Abstract P3–09–15: a phase 1b study of PVX-410 (PVX) vaccine plus durvalumab (DUR) as adjuvant therapy in HLA-A2+ early stage triple negative breast cancer (eTNBC) to assess safety and immune response. Cancer Research. 2020;80(4_Supplement):P3–09–15-P3–09–15.

Isakoff SJ, Tung NM, Yin J, Tayob N, Parker J, Rosenberg J, et al. Abstract P2–14–17: a phase 1b study of PVX-410 vaccine in combination with pembrolizumab in metastatic triple negative breast cancer (mTNBC). Cancer Research. 2022;82(4_Supplement):P2–14–17-P2–14–7.

Patel M, Jimeno A, Wang D, Stemmer S, Bauer T, Sweis R, et al. 539 Phase 1 study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L/IL-23/IL-36γ, for intratumoral (ITu) injection +/- durvalumab in advanced solid tumors and lymphoma. J Immunother Cancer. 2021;9(Suppl 2):A569–A569.

Article  Google Scholar 

Corti C, Venetis K, Sajjadi E, Zattoni L, Curigliano G, Fusco N. CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. Expert Opin Investig Drugs. 2022;31(6):593–605.

Article  CAS  PubMed  Google Scholar 

Toulouie S, Johanning G, Shi Y. Chimeric antigen receptor T-cell immunotherapy in breast cancer: development and challenges. J Cancer. 2021;12(4):1212–9.